Bluebird Bio completed the spinoff of its cancer business earlier this month, leaving the company with Obenshain, who was previously president of the company’s genetic diseases business, at the helm—as well as three late-stage gene therapy candidates for severe genetic diseases; a partnered Phase I short hairpin RNA (shRNA)-based treatment targeting BCL11A mRNA for sickle-cell disease (SCD); and “multiple” undisclosed preclinical candidates . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge